Division of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI, USA.
Surg Clin North Am. 2013 Apr;93(2):473-91. doi: 10.1016/j.suc.2012.12.002. Epub 2013 Feb 8.
Although some women with early breast cancer (BC) may be cured with loco-regional treatment alone, up to 20% of patients with early-stage BC will ultimately experience treatment failure and recurrence. A substantial portion of the success in improving clinical outcomes of patients with BC is related to the standardized use of adjuvant therapies. The identification of tumor subtypes with prognostic value has contributed to the idea of tailoring treatments using biologic predictive factors to identify the patients who will most likely respond to therapy and minimize the exposure of "nonresponders" to the side effects of the treatment.
尽管一些早期乳腺癌（BC）女性仅通过局部区域治疗就可能被治愈，但多达 20%的早期 BC 患者最终将经历治疗失败和复发。改善 BC 患者临床结局的成功很大程度上与辅助治疗的标准化使用有关。具有预后价值的肿瘤亚型的鉴定有助于采用生物预测因素来制定治疗方案的理念，以确定最有可能对治疗有反应的患者，并使“无反应者”最小化暴露于治疗副作用的风险。
